+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Checkpoint Proteins Market - Global Forecast 2025-2030- Product Image
Immune Checkpoint Proteins Market - Global Forecast 2025-2030- Product Image
Sale

Immune Checkpoint Proteins Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6129650
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Immune checkpoint protein therapeutics are reshaping oncology strategies for pharmaceutical leaders, providing new potential to improve cancer patient outcomes through targeted mechanisms of action and informed regulatory collaboration.

Market Snapshot: Immune Checkpoint Protein Therapeutics

The global immune checkpoint protein therapeutics market is advancing as rapidly evolving clinical innovations and regulatory adaptations drive adoption worldwide. Strong investment persists across biopharma, with multinational alliances and agile biotech firms pushing next-generation therapies through robust pipelines. As decision-makers navigate increasingly complex supply chains, manufacturing requirements, and pricing pressures, real-world evidence and differentiated positioning become central to sustaining growth. Heightened attention on combination regimens and biomarker-guided protocols demonstrates a marked industry shift toward individualizing treatment and expediting market access, supporting the adoption of immune checkpoint protein therapeutics across diverse healthcare settings.

Scope & Segmentation

This report provides a comprehensive view of the immune checkpoint protein therapeutics market, focusing on major segments that define its scope:

  • Target Molecules: CTLA-4 inhibitors (ipilimumab), PD-1 inhibitors (cemiplimab, nivolumab, pembrolizumab), and PD-L1 inhibitors (atezolizumab, avelumab, durvalumab).
  • Indications: Addressing head and neck cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, and urothelial carcinoma.
  • Therapy Types: Both monotherapy and combination therapy modalities, with a focus on novel regimens that leverage collaborative mechanisms of action.
  • End Users: Ambulatory surgical centers, hospitals, and oncology clinics, reflecting varying procurement channels and patient management practices.
  • Formulations: Injectable infusion and injectable subcutaneous options, matching both standard protocols and convenience-centered approaches.
  • Regions: Coverage spans the Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with markets such as United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, and more), and Asia-Pacific (including China, India, Japan, Australia, South Korea, and Southeast Asian growth centers).
  • Companies Analyzed: Merck & Co., Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; AstraZeneca PLC; Pfizer Inc.; Merck KGaA; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Johnson & Johnson; Novartis AG.

Technological and Regional Relevance

Adoption accelerates where health infrastructure aligns with regulatory facilitation and local manufacturing. Regional trends indicate early uptake in North America and Western Europe, strategic alliances across Asia-Pacific, and regulatory harmonization efforts in Latin America and emerging economies. Technology use includes advanced analytics, biomarker companion diagnostics, and modular production platforms.

Key Takeaways for Senior Decision-Makers

  • The immune checkpoint protein therapeutics space is shifting to combination protocols, emphasizing patient stratification and real-world data to enhance clinical relevance.
  • Pharmaceutical organizations are prioritizing pipeline diversity by integrating internal R&D with strategic collaborations to strengthen their competitive position.
  • Manufacturing and supply chain resilience have become pivotal, with modular and localized production addressing potential disruptions and tariff uncertainties.
  • Stakeholders are leveraging volume agreement structures with payers to mitigate input cost fluctuations driven by evolving trade measures and supply chain dependencies.
  • Regional expansion strategies depend on tailored engagement with local healthcare systems, aligning reimbursement frameworks and regulatory expectations for effective market entry.

Tariff Impact and Strategic Response

New U.S. tariffs implemented in 2025 impact upstream manufacturing costs for immune checkpoint protein therapeutics, increasing the need for manufacturers to assess supplier diversity and sourcing localization. Biopharma developers are responding by strengthening procurement alliances, activating local fill-finish operations, and prioritizing high-value assets in R&D portfolios. These factors also influence hospital and clinic purchasing behaviors, leading to more rigorous value assessments and extended procurement cycles.

Robust Research Methodology & Data Sources

This analysis employs a blend of primary and secondary data sources, involving interviews with oncology specialists, regulatory experts, and supply chain leaders. Secondary research integrates peer-reviewed articles, regulatory filings, clinical trial registries, and company disclosures. Analytical frameworks were cross-validated by expert panels to ensure comprehensive, actionable insights.

Why This Report Matters

  • Enables decision-makers to anticipate regulatory shifts, optimize market entry, and develop cross-segment strategies grounded in current clinical and real-world trends.
  • Delivers a holistic perspective on regional variation and supply chain resilience, supporting long-term planning and investment decisions across global oncology markets.

Conclusion

Integrating scientific advancement, regulatory complexity, and evolving market dynamics, this report equips senior leaders to strategically position their organizations for success in the immune checkpoint protein therapeutics market.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surge in clinical development of bispecific antibody therapies targeting PD-1 and CTLA-4 pathways for resistant solid tumors
5.2. Integration of tumor mutational burden and liquid biopsy biomarkers to optimize immune checkpoint inhibitor patient selection and outcomes
5.3. Strategic partnerships between biotechs and Big Pharma to accelerate next-generation checkpoint inhibitor pipeline expansion and commercialization
5.4. Adoption of combination regimens pairing PD-1 inhibitors with targeted kinase inhibitors to overcome resistance mechanisms in advanced melanoma
5.5. Health economics and outcomes research guiding value-based pricing and reimbursement of immune checkpoint therapies across global markets
5.6. Advancement of novel checkpoint targets like TIGIT and LAG-3 following FDA approval of relatlimab in metastatic melanoma
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immune Checkpoint Proteins Market, by Target Molecule
8.1. Introduction
8.2. Ctla-4 Inhibitors
8.2.1. Ipilimumab
8.3. Pd-1 Inhibitors
8.3.1. Cemiplimab
8.3.2. Nivolumab
8.3.3. Pembrolizumab
8.4. Pd-L1 Inhibitors
8.4.1. Atezolizumab
8.4.2. Avelumab
8.4.3. Durvalumab
9. Immune Checkpoint Proteins Market, by Indication
9.1. Introduction
9.2. Head And Neck Cancer
9.3. Melanoma
9.4. Non-Small Cell Lung Cancer
9.5. Renal Cell Carcinoma
9.6. Urothelial Carcinoma
10. Immune Checkpoint Proteins Market, by Therapy Type
10.1. Introduction
10.2. Combination Therapy
10.3. Monotherapy
11. Immune Checkpoint Proteins Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospital
11.4. Oncology Clinics
12. Immune Checkpoint Proteins Market, by Formulation
12.1. Introduction
12.2. Injectable Infusion
12.3. Injectable Subcutaneous
13. Americas Immune Checkpoint Proteins Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Immune Checkpoint Proteins Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Immune Checkpoint Proteins Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. Bristol-Myers Squibb Company
16.3.3. F. Hoffmann-La Roche Ltd
16.3.4. AstraZeneca PLC
16.3.5. Pfizer Inc.
16.3.6. Merck KGaA
16.3.7. Regeneron Pharmaceuticals, Inc.
16.3.8. Sanofi S.A.
16.3.9. Johnson & Johnson
16.3.10. Novartis AG
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. IMMUNE CHECKPOINT PROTEINS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. IMMUNE CHECKPOINT PROTEINS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. IMMUNE CHECKPOINT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. IMMUNE CHECKPOINT PROTEINS MARKET: RESEARCHAI
FIGURE 26. IMMUNE CHECKPOINT PROTEINS MARKET: RESEARCHSTATISTICS
FIGURE 27. IMMUNE CHECKPOINT PROTEINS MARKET: RESEARCHCONTACTS
FIGURE 28. IMMUNE CHECKPOINT PROTEINS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IMMUNE CHECKPOINT PROTEINS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY AVELUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY UROTHELIAL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY UROTHELIAL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INJECTABLE INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INJECTABLE INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 106. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 107. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 108. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 109. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 110. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 111. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 116. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 117. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 136. MEXICO IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 204. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 205. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 214. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 215. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 218. GERMANY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 220. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 221. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 230. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 231. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 234. FRANCE IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 251. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 252. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 253. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 258. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 259. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 262. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 263. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 266. ITALY IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 267. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 268. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 269. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 278. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 279. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 282. SPAIN IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY TARGET MOLECULE, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA IMMUNE CHECKPOINT PROTEINS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA I

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immune Checkpoint Proteins Market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Pfizer Inc.
  • Merck KGaA
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Novartis AG

Related Reports

Solid Tumors Target Proteins Market - Global Forecast 2025-2030 - Product Image

Solid Tumors Target Proteins Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Cancer Monoclonal Antibodies Market - Global Forecast 2025-2030 - Product Image

Cancer Monoclonal Antibodies Market - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Biologics Targeting CCR4 Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Biologics Targeting CCR4 Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Cancer Therapeutics and Biotherapeutics - Global Strategic Business Report - Product Image

Cancer Therapeutics and Biotherapeutics - Global Strategic Business Report

  • Report
  • 419 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.